Financing led by institutional life sciences investor, with participation from new and existing investors

由机构生命科学投资者主导的融资，新投资者和现有投资者均有参与

Capital expected to support expansion of CDMO platform and advancement of customer programs

预计资本将支持CDMO平台的扩展和客户项目的推进。

JERUSALEM

耶路撒冷

,

，

April 24, 2026

2026年4月24日

/PRNewswire/ --

/PRNewswire/ --

Scinai Immunotherapeutics Ltd.

赛诺免疫治疗有限公司

(NASDAQ:

（纳斯达克：

SCNI

中国科学院神经科学研究所

), ('Scinai' or the 'Company') a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of

），（“Scinai”或“公司”）是一家推进一系列创新炎症和免疫学治疗药物的生物制药公司，同时也是

Scinai Biopharma Services Ltd

知临生物制药服务有限公司

., a contract development and manufacturing organization (CDMO), today announced that it has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and accredited investors, for the purchase and sale of 5,208,333 American Depositary Shares (ADSs), each representing 4,000 ordinary shares, at a purchase price of $0.48 per ADS, as well as a Series A warrant to purchase up to 5,208,333 ADSs at an exercise price of $0.48 per ADS, exercisable immediately with a term of two years, and a Series B warrant to purchase up to 5,208,333 ADSs at an exercise price of $0.55 per ADS, exercisable immediately with a term of five years..

., 一家合同开发和制造组织（CDMO），今天宣布已与一家机构生命科学投资者以及新的和现有的机构和合格投资者签订了证券购买协议，以每股0.48美元的价格购买和出售5,208,333份美国存托股份（ADS），每份ADS代表4,000股普通股。此外，还包括一项A类认股权证，可立即行使，期限为两年，允许以每股0.48美元的价格购买最多5,208,333份ADS；以及一项B类认股权证，可立即行使，期限为五年，允许以每股0.55美元的价格购买最多5,208,333份ADS。

In addition, the Company entered into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of warrants to purchase up to 229,310 ADSs of its ordinary shares (the 'Existing Warrants') at an exercise price of $0.48 per ADS.

此外，公司与公司现有的一家机构投资者签订了认股权证诱导协议，该投资者将立即行使认股权证，以每股0.48美元的价格购买至多229,310股公司普通股的美国存托股份（“现有认股权证”）。

In consideration for the immediate exercise in full of the Existing Warrants for cash, the investor will receive in a private placement new unregistered warrants to purchase up to 458,621 ADSs (the 'New Warrants'). The New Warrants will have an exercise price of $0.55 per ADS, will be exercisable immediately, and will expire five (5) years from the date of issuance..

鉴于投资者已全额现金行使现有认股权证，作为对价，投资者将通过私募方式获得可购买多达458,621股美国存托股份（ADS）的新未注册认股权证（“新认股权证”）。新认股权证的行权价格为每股ADS 0.55美元，可立即行权，并于发行之日起五年后到期。

The aggregate gross proceeds from the private placement and the warrant inducement transaction are approximately $2.61 million, before deducting fees and expenses, and the closing of the transactions is expected to occur on or about April 27, 2026, subject to satisfaction of customary closing conditions..

私募配售和认股权证诱导交易的总收益约为 261 万美元，在扣除费用和开支之前，预计交易将于 2026 年 4 月 27 日或左右完成，但需满足惯例的交割条件。

Scinai intends to use the net proceeds, together with existing cash resources, to support the expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. The Company believes this financing will support the execution of its growth strategy..

Scinai 打算将所得净收益与现有现金资源一起用于支持其 CDMO 平台的扩展、推动客户项目，并继续有选择地投资于其免疫治疗管线。公司认为，此次融资将有助于执行其增长战略。

A.G.P./Alliance Global Partners acted as the sole financial advisor for the transactions.

A.G.P./Alliance Global Partners 担任了这些交易的唯一财务顾问。

The offer and sale of the foregoing securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws..

前述证券的要约和出售将依赖《1933年证券法》（经修订）第4(a)(2)条规定的注册豁免以及据此颁布的D条例进行。因此，在私募中发行的证券在美国境内不得进行要约或出售，除非依据有效的注册声明或适用的《证券法》及相应的州证券法注册要求的豁免。

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in this warrant inducement transaction, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或购买任何与本次认股权证诱导交易相关的证券的要约或要约邀请，且在任何州或其他司法管辖区，不得在根据该等州或其他司法管辖区的证券法进行注册或资格认证之前，进行此类要约、要约邀请或证券销售（若此类行为属于违法）。

About Scinai Immunotherapeutics

关于Scinai免疫治疗学

Scinai Immunotherapeutics Ltd. (NASDAQ:

Scinai免疫治疗有限公司（纳斯达克：

SCNI

中国科学院神经科学研究所

) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

是一家专注于开发创新免疫疗法的生物制药公司。该公司正在推进从马克斯·普朗克学会和PinCell S.r.l.授权的治疗候选药物管线。

Scinai also owns

斯奇纳伊还拥有

Scinai Biopharma Services Ltd

知临生物制药服务有限公司

., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

一家合同开发和制造组织 (CDMO)，为生物技术和制药公司提供开发和制造服务。

For more information, please visit:

欲了解更多信息，请访问：

www.scinai.com

www.scinai.com

Company Contacts

公司联系人

Business Development | +972 8 930 2529 |

业务发展 | +972 8 930 2529 |

[email protected]

电子邮件地址

Investor Relations – Allele Capital Partners | +1 978 857 5075 |

投资者关系 – Allele Capital Partners | +1 978 857 5075 |

[email protected]

电子邮件地址

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed closing of the transactions, the expected timing and terms thereof, the expected gross proceeds, the intended use of proceeds, the Company's ability to expand its CDMO platform, execute on its growth strategy and business development opportunities, advance its R&D pipeline, and realize the expected benefits of its acquisition of Recipharm Israel and related commercial collaboration..

本新闻稿包含根据1995年美国私人证券诉讼改革法案及其他适用证券法律定义的前瞻性陈述。前瞻性陈述包括但不限于关于拟议交易完成、预期时间与条款、预期总收益、收益用途、公司扩展其CDMO平台的能力、执行其增长战略和业务发展机会、推进其研发管线，以及实现收购Recipharm以色列及相关商业合作的预期效益的陈述。

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks related to the completion of the financing, the Company's ability to successfully deploy the proceeds, integrate acquired operations, attract and retain customers, expand its CDMO activities, advance its product candidates, secure partnerships, execute on its growth strategy and general market and industry conditions.

这些声明基于当前的预期和假设，并受到风险和不确定性的制约，可能导致实际结果与这些声明所表达或暗示的内容有重大差异。这些风险和不确定性包括但不限于：与融资完成相关的风险、公司成功部署所得款项的能力、整合收购业务、吸引和留住客户、扩展其CDMO活动、推进其产品候选项目、确保合作伙伴关系、执行其增长战略以及总体市场和行业状况。

More detailed information regarding these and other risks and uncertainties is included in the Company's filings with the U.S. Securities and Exchange Commission..

有关这些风险和不确定性的更多详细信息包含在公司向美国证券交易委员会提交的文件中。

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.

前瞻性声明仅截至本新闻稿发布之日。除非适用法律要求，公司不承担任何更新或修改前瞻性声明以反映新信息、未来事件或其他情况的义务。

Logo:

标志：

https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

SOURCE Scinai Immunotherapeutics Ltd.

来源：Scinai免疫治疗有限公司。

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示